Patents by Inventor Urban Lundberg
Urban Lundberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067681Abstract: The present invention relates to modified hMPV F proteins stabilized in the pre-fusion conformation as vaccine candidates.Type: ApplicationFiled: October 24, 2023Publication date: February 29, 2024Applicant: Valneva SEInventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
-
Publication number: 20240026412Abstract: The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).Type: ApplicationFiled: April 9, 2021Publication date: January 25, 2024Applicant: Valneva Austria GmbHInventors: Robert Schlegl, Franz Moisi, Markus Hanner, Urban Lundberg
-
Publication number: 20230322869Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: January 6, 2023Publication date: October 12, 2023Applicant: Valneva Austria GmbHInventors: URBAN LUNDBERG, Wolfgang Schüler
-
Publication number: 20230295245Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: September 14, 2022Publication date: September 21, 2023Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20230293661Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.Type: ApplicationFiled: September 26, 2022Publication date: September 21, 2023Applicant: Valneva SEInventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
-
Publication number: 20230151063Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.Type: ApplicationFiled: April 13, 2018Publication date: May 18, 2023Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Andreas Meinke, Abhijeet Nayak, Wolfgang Schüler
-
Patent number: 11572392Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: August 11, 2020Date of Patent: February 7, 2023Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 11466058Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: December 4, 2019Date of Patent: October 11, 2022Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20220185847Abstract: The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections.Type: ApplicationFiled: May 19, 2020Publication date: June 16, 2022Applicant: Valneva SEInventors: Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
-
Publication number: 20220185851Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: November 2, 2021Publication date: June 16, 2022Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Patent number: 11357846Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.Type: GrantFiled: August 20, 2021Date of Patent: June 14, 2022Assignee: Valneva SEInventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schiegl, Arnaud Leon
-
Publication number: 20220016230Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.Type: ApplicationFiled: August 20, 2021Publication date: January 20, 2022Applicant: Valneva SEInventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
-
Patent number: 11208439Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: February 27, 2018Date of Patent: December 28, 2021Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Publication number: 20210054032Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: August 11, 2020Publication date: February 25, 2021Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Patent number: 10766931Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: April 4, 2018Date of Patent: September 8, 2020Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Publication number: 20200239525Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: December 4, 2019Publication date: July 30, 2020Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Patent number: 10544194Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: September 22, 2016Date of Patent: January 28, 2020Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
-
Publication number: 20180362593Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: April 4, 2018Publication date: December 20, 2018Applicant: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler
-
Publication number: 20180327460Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: ApplicationFiled: February 27, 2018Publication date: November 15, 2018Applicant: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
-
Patent number: 9975927Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: January 9, 2015Date of Patent: May 22, 2018Assignee: Valneva Austria GmbHInventors: Urban Lundberg, Wolfgang Schüler